StreetAlpha
13F holdings · Q3 2026

Artia Global Partners

Miami, FL · files as Artia Global Partners LP
Know the moment Artia Global Partners filesYou follow Artia Global Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1937964

Artia Global Partners reported 50 stocks worth $492M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are INSM (13.7%), RVMD (7.7%) and ABVX (7.3%). Compared with Q2 2026, the fund opened new positions in RVTY, BRKR and TMO, added to BTSG, TVTX and GH, trimmed ABVX, CELC and EYPT and sold out of IONS, ALMS and SION.

Latest filing: what Artia Global Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
12 new9 added4 trimmed9 sold outBought about $71.8M · sold about $54.2M
New 12
See all 12 →
Added 9
See all 9 →
Trimmed 4
Sold out 9
See all 9 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$492M−6.5% vs last quarter
Stocks held5012 new · 9 sold out
Top 5 weight42.2%fairly concentrated
Turnover26%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
INSM
Insmed Inc
$67.2M13.7%589KNo change8 of 8
2
RVMD
Revolution Medicines Inc
$38.1M7.7%185KNo change8 of 8
3
ABVX
Abivax SA
$36.1M7.3%364K−152K (−29%)5 of 8
4
BTSG
Brightspring Health Svcs Inc
$34.6M7.0%610K+93K (+18%)5 of 8
5
TRVI
Trevi Therapeutics Inc
$31.7M6.4%2.2MNo change6 of 8
6
ARGX
Argenx SE
$28.5M5.8%30KNo change8 of 8
7
TVTX
Travere Therapeutics Inc
$23.5M4.8%398K+59K (+18%)7 of 8
8
ALKS
Alkermes PLC
$18.2M3.7%449KNo change2 of 8
9
GH
Guardant Health Inc
$17.2M3.5%97K+59K (+154%)2 of 8
10
AZN
Astrazeneca PLC Ord
$15.9M3.2%98KNo change3 of 8
🔒 40 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
IONS
Ionis Pharmaceuticals Inc
$11.4M144K
ALMS
Alumis Inc
$7.8M279K
SION
Sionna Therapeutics Inc
$5.3M120K
PALI
Palisade Bio Inc
$4.2M2M
XENE
Xenon Pharmaceuticals Inc
$3.9M65K

🔒 Free account: see all 9.

Options

valued at the underlying shares
StockTypeValueSharesChange
MRNA
Moderna Inc
Put$3.9M20K+20,000

Reported value

last 8 quarters
$248MQ4 '24
$341MQ1 '25
$389MQ2 '25
$568MQ3 '25
$622MQ4 '25
$444MQ1 '26
$526MQ2 '26
$492MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Artia Global Partners 13F FAQ

What does Artia Global Partners own?

Artia Global Partners reported 50 stocks worth $492M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are INSM (13.7%), RVMD (7.7%) and ABVX (7.3%). The table above lists every position in the filing (the top 10 without an account).

What did Artia Global Partners buy and sell in Q3 2026?

Compared with Q2 2026: 12 new positions, 9 added to, 4 trimmed and 9 sold out. New positions include RVTY, BRKR and TMO. It sold all of IONS, ALMS and SION.

When will Artia Global Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Artia Global Partners's portfolio worth?

The Q3 2026 filing reports $492M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.